תוצאות חיפוש - Dirk Huebner

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas

    Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas מאת Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard A. Lutes, Andy Chi, Stefano Pileri

    יצא לאור 2016
    קבל טקסט מלא
    Revisão
    הוספה למועדפים
    שמור ב:
  2. 2
    Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom

    Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom מאת Paul J. Bröckelmann, Suzanne McMullen, Jake Wilson, Kerstin Mueller, Sarah Goring, Aspasia Stamatoullas, Erin Zagadailov, Ashish Gautam, Dirk Huebner, Mehul Dalal, Tim Illidge

    יצא לאור 2018
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  3. 3
    Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma מאת Robert Chen, Ajay K. Gopal, Scott E. Smith, Stephen M. Ansell, Joseph D. Rosenblatt, Kerry J. Savage, Joseph M. Connors, Andreas Engert, Emily K. Larsen, Dirk Huebner, Abraham Fong, Anas Younes

    יצא לאור 2016
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  4. 4
    Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30<sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study

    Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30<sup>+</sup> Peripheral T-Cell Lymphomas: Results of a Phase I Study מאת Michelle A. Fanale, Steven M. Horwitz, Andres Forero‐Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Dirk Huebner, Dana A. Kennedy, Andrei R. Shustov

    יצא לאור 2014
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  5. 5
    Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

    Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies מאת Nancy L. Bartlett, Robert Chen, Michelle A. Fanale, Pauline Brice, Ajay K. Gopal, Scott E. Smith, Ranjana H. Advani, Jeffrey Matous, Radhakrishnan Ramchandren, Joseph D. Rosenblatt, Dirk Huebner, Pamela Levine, Laurie E. Grove, Andres Forero‐Torres

    יצא לאור 2014
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  6. 6
    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

    Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma מאת Barbara Pro, Ranjana H. Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle A. Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan Pinelli, Dana A. Kennedy, Andrei R. Shustov

    יצא לאור 2017
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  7. 7
    Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

    Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomise... מאת Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi, Edward Agura, Jerzy Hołowiecki, Muneer H. Abidi, Andy I. Chen, Patrick J. Stiff, Alessandro M. Gianni, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanová, John Sweetenham, Anna Sureda, Dirk Huebner, Eric L. Sievers, Andy Chi, Emily K. Larsen, Naomi Hunder, Jan Walewski

    יצא לאור 2015
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  8. 8
    Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial

    Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial מאת Stefan Faderl, Meir Wetzler, David A. Rizzieri, Gary J. Schiller, Madan Jagasia, Robert K. Stuart, Siddhartha Ganguly, David Avigan, Michael Craig, Robert H. Collins, Michael B. Maris, Tibor Kovacsovics, Stuart L. Goldberg, Karen Seiter, Parameswaran Hari, Jochen Greiner, Norbert Vey, Christian Récher, Farhad Ravandi, Eunice S. Wang, Michael J. Vasconcelles, Dirk Huebner, Hagop M. Kantarjian

    יצא לאור 2012
    קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:
  9. 9
    Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma מאת Joseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won S. Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier Luigi Zinzani, David Cunningham, András Rosta, Neil C. Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina Jolin, Dirk Huebner, John Radford

    יצא לאור 2017
    קבל טקסט מלא קבל טקסט מלא
    Artigo
    הוספה למועדפים
    שמור ב:

כלי חיפוש: